Disruption of Interleukin-1[beta] Autocrine Signaling Rescues Complex I Activity and Improves ROS Levels in Immortalized Epithelial Cells with Impaired Cystic Fibrosis Transmembrane Conductance Regulator

• Published in: PloS one Vol. 9; no. 6
• Main Authors: Clauzure, Mariángeles, Valdivieso, Angel G, Massip Copiz, María M, Schulman, Gustavo, Teiber, María Luz, Santa-Coloma, Tomás A
• Format: Journal Article
• Language: English
• Published: Public Library of Science 05.06.2014
• Subjects: Cystic fibrosis; Interleukins; Proteins; RNA
• DOI: 10.1371/journal.pone.0099257
• ISSN: 1932-6203

Patients with cystic fibrosis (CF) have elevated concentration of cytokines in sputum and a general inflammatory condition. In addition, CF cells in culture produce diverse cytokines in excess, including IL-1[beta]. We have previously shown that IL-1[beta], at low doses (~30 pM), can stimulate the expression of CFTR in T84 colon carcinoma cells, through NF-[kappa]B signaling. However, at higher doses (>2.5 ng/ml, ~150 pM), IL-1[beta] inhibit CFTR mRNA expression. On the other hand, by using differential display, we found two genes with reduced expression in CF cells, corresponding to the mitochondrial proteins CISD1 and MTND4. The last is a key subunit for the activity of mitochondrial Complex I (mCx-I); accordingly, we later found a reduced mCx-I activity in CF cells. Here we found that IB3-1 cells (CF cells), cultured in serum-free media, secrete 323±5 pg/ml of IL-1[beta] in 24 h vs 127±3 pg/ml for S9 cells (CFTR-corrected IB3-1 cells). Externally added IL-1[beta] (5 ng/ml) reduces the mCx-I activity and increases the mitochondrial (MitoSOX probe) and cellular (DCFH-DA probe) ROS levels of S9 (CFTR-corrected IB3-1 CF cells) or Caco-2/pRSctrl cells (shRNA control cells) to values comparable to those of IB3-1 or Caco-2/pRS26 cells (shRNA specific for CFTR). Treatments of IB3-1 or Caco-2/pRS26 cells with either IL-1[beta] blocking antibody, IL-1 receptor antagonist, IKK inhibitor III (NF-[kappa]B pathway) or SB203580 (p38 MAPK pathway), restored the mCx-I activity. In addition, in IB3-1 or Caco-2/pRS26 cells, IL-1[beta] blocking antibody, IKK inhibitor III or SB203580 reduced the mitochondrial ROS levels by ~50% and the cellular ROS levels near to basal values. The AP-1 inhibitors U0126 (MEK1/2) or SP600125 (JNK1/2/3 inhibitor) had no effects. The results suggest that in these cells IL-1[beta], through an autocrine effect, acts as a bridge connecting the CFTR with the mCx-I activity and the ROS levels.